Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

RP-L102, which the firm designed to treat a form of disease caused by FANCA mutations, is already under review with the European Medicines Agency.

LakeShore Biopharma has commenced the submission of its biologics license application (BLA) to the Drug Regulatory Authority ...

Josh Jennings’s rating is based on several key factors. First, Humacyte’s recent third-quarter results have shown promising signs, particularly as their Biologics License Application (BLA) for ...

DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...

At the center of this fight is how the FDA regulates a possible "functional cure" for Type 1 diabetes and determines who gets ...

WuXi XDC Cayman Inc. ('WuXi XDC' or the 'Company', stock code: 2268.HK), a leading global CRDMO (Contract Research, ...

Autolus Technologies announced in January 2024 that the FDA had accepted its Biologics License Application for obe-cel and noted the treatment had also been granted Orphan Drug Designation by the FDA.

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global leader ...

The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...